Product Compliance And Certification For Medical Device In Brazil

Scope and evidence must be confirmed before any paid tests or filings.

Medical-device compliance in Brazil is not one universal “certificate”. For a defined product, establish whether it is a medical device or an in-vitro diagnostic (IVD), assign the Brazilian risk class from its intended use, and then test the additional certification, company, evidence, labelling and post-market layers. This is a product-route map, not a substitute for the device-specific classification decision.

Classify the actual product, not its marketing category

Write a controlled intended-purpose statement first: clinical claim; patient or sample; professional or lay user; point of use; invasiveness and duration of contact; power source; software outputs; and whether a diagnostic result is obtained from a human specimen. Under RDC 751/2022, ordinary devices use 22 classification rules, with the higher-risk rule applying where several functions qualify. For specimen-based IVDs, including IVD instruments, use RDC 830/2023 instead.

The relevant Brazilian classes are I–IV. Classes I–II ordinarily follow notificação (notification); classes III–IV follow registro (registration). Notification is not an exemption from safety, technical-dossier or surveillance responsibilities. A product marketed abroad as “wellness”, “CE certified” or “FDA cleared” does not acquire a Brazilian classification merely from that label.

Before choosing either route, check whether the product is regulated as a medical device at all. ANVISA maintains a list of items not regularised as medical devices, including specified general-purpose laboratory equipment, hospital support products and products exclusively for research use (RUO). Scope depends on the actual intended use and presentation: a clinical diagnostic claim can change the analysis. Being outside medical-device regularisation does not establish exemption from other applicable rules.

Cross-regime matrix: which approvals can accumulate?

Product trigger	Potential additional regulatory layer	Decision before investment
General-purpose laboratory, hospital-support or research-only product without a medical-device intended purpose	Potential exclusion from ANVISA medical-device regularisation, according to ANVISA’s official non-regulated product list; other laws may still apply.	Record claims and use conditions, compare the exact product with the official list, and do not treat an RUO label alone as a conclusive classification.
Device makes a medical claim without IVD specimen analysis	ANVISA RDC 751/2022: class I–IV; notification or registration; RDC 848/2024 essential safety/performance	Fix intended purpose, apply the specific risk rule, identify models and accessories.
Reagent, test kit, control, analyser or other product for examination of human specimens	ANVISA RDC 830/2023 IVD class and route; analytical/clinical performance where relevant	Separate instrument, test, calibrator and sample-collection claims; verify whether any special IVD rule applies.
Electromedical or other equipment within compulsory SBAC scope	RDC 549/2021 plus the applicable ANVISA normative list (ANVISA identifies IN 283/2024); INMETRO-accredited certification body	Identify the exact equipment category, model and standard editions before booking tests.
Needle, syringe, glove, breast implant or another specially regulated commodity	Product-specific ANVISA rules may impose additional SBAC certification or technical specifications	Identify the exact commodity regulation; do not assume all non-electrical products are exempt.
Wireless telemetry, Wi-Fi, Bluetooth or cellular radio functions	Potential separate ANATEL conformity assessment / homologation for the radio product	Check RF module, final-equipment configuration and which ANATEL approval is applicable.
Standalone clinical software or device software providing a medical function	RDC 657/2022 for SaMD; product classification under RDC 751/2022, with IVD-specific intersection where relevant	Distinguish SaMD, embedded software and software exclusively accessory to a regulated device.
Imported product and Brazilian distribution chain	Brazil-based product holder; relevant AFE and local sanitary licence; import clearance checks	Identify the holder and importer separately, verify activity coverage and written manufacturer authority.
Device enters the market or changes after launch	RDC 591/2021 UDI implementation, technical vigilance, field actions and change rules	Verify the risk-class-specific UDI obligation and assess whether changes alter the filed product.
Spare part or accessory imported separately	ANVISA distinguishes spare parts and accessories already covered by a finished-device regularisation from accessories regularised as devices in their own right; AFE requirements can differ.	Identify the host device, approved accessory scope and import purpose; review the importer’s AFE and import consent independently.
Used or refurbished medical device, particularly an implant	RDC 579/2021 creates a separate route and restrictions; ANVISA says used or refurbished implantable devices cannot be imported, marketed or donated.	Identify the product’s history and implantable status before contracting shipment; a normal device registration does not eliminate a prohibition.

A technical standard recognised by ANVISA is not itself an approval, product certificate or proof that compulsory INMETRO/SBAC certification applies. First identify the binding product regulation and its current scope.

Evidence matrix: what must be ready before the route is fixed?

Do not commission every test before classification. Build a product-specific evidence register with a named owner for each item.

Evidence packet	Why it matters	Go/no-go question
Intended use, claims, IFU draft, users and device architecture	Controls device/IVD scope, risk rule, separate software and accessory classification	Do promotional claims exceed what has been technically validated?
Technical dossier, risk-management file, safety/performance verification, clinical or IVD performance data	Demonstrates conformity with RDC 848/2024 and the evidence appropriate to the product	Is there adequate evidence for each intended purpose, model and claimed user population?
Design/model list; electrical, EMC, radio and commodity test reports as applicable	Determines potential SBAC/ANATEL overlays and the certificate/model scope	Are test reports for the exact production configuration and applicable Brazilian standard edition?
Manufacturing sites, quality system and GMP/CBPF status	RDC 665/2022 GMP baseline; ANVISA GMP certificate can gate higher-risk registration	Is a relevant CBPF in place or does certification need a separate workstream?
Legal manufacturer authorisation, Brazilian holder/importer details, labels and traceability plan	Connects the filed product, legal responsibility, Portuguese user information and post-market action	Can every marketed SKU be matched to its filed identity and responsible company?

IVD decisions require an additional check: certain self-tests are prohibited, and some high-risk IVD assays need official-laboratory performance assessment. Confirm intended user, analyte and methodology before assuming an eligible self-test or that manufacturer test data alone suffice.

Who holds the Brazilian authorisation and when may sales begin?

An overseas manufacturer does not file directly as the Brazilian marketing-authorisation holder. Confirm a legally established Brazilian applicant/holder (detentor), manufacturer authorisation, the legal importer and relevant operating authorisations (AFE) and local sanitary licences. AFE coverage is activity- and establishment-specific; do not confuse an importer, a distributor and a holder. Verify exceptions rather than assuming every business needs the same permit.

For applicable classes III–IV, assess ANVISA Good Manufacturing Practices certification (CBPF) independently of product registration; RDC 665/2022 sets the GMP framework. ANVISA describes a protocol-to-apply pathway for certain equipment, but effective authorisation remains conditional on published GMP certification. If the product also needs SBAC or ANATEL approval, ANVISA regularisation by itself is not a substitute. A foreign CE mark or FDA clearance is supporting evidence, not automatic Brazilian market permission.

Portuguese labelling, IFU and UDI must match the product

Build Brazilian Portuguese label and instructions-for-use (IFU) masters from the same approved intended purpose and model list. Verify legal manufacturer and Brazilian holder identifiers, ANVISA number, intended users, warnings, sterile/reuse status, lot or serial, expiry or shelf life and storage conditions where applicable. IVD rules under RDC 830/2023 expressly require Portuguese user information and specific contents for primary and secondary labels; requirements for non-IVD devices must be checked against RDC 751/2022. Do not assume electronic-only IFUs are allowed for every device or user.

UDI is a separate traceability programme under RDC 591/2021. ANVISA states that the SIUD database has operated since 1 March 2026 under IN 426/2026, with staggered requirements linked to device risk class and obligation type. Review the current official schedule before printing identifiers or declaring a particular product overdue. A change to indications, model, firmware, intended users, manufacturer or labelling may demand both a regulatory change assessment and traceability update.

Launch-release and change-control gates

Scope freeze — Approve claims, device/IVD distinction, class/rule, product family boundary and all Brazilian model variants.
Overlay check — Decide separately on SBAC/INMETRO, special commodity rules, ANATEL radio approval and CBPF; record non-applicability rationales.
Evidence and holder readiness — Complete dossier gap review, performance and test plan, Brazilian holder/importer permissions and controlled Portuguese labelling.
Commercial release and maintenance — Verify the published notification or granted registration and all independent approvals before commercial importation or sale; thereafter monitor UDI, complaints, field actions and change filings.

Before release, compare the holder, product identity and current status against ANVISA’s public product consultation. If coverage of a particular model or accessory remains unclear, check the underlying authorisation; a visible number is not proof that every variant is covered.

For notification and registration alike, ANVISA describes publication of the act in the Diário Oficial da União (DOU) as the point after which the authorised product may be marketed; the filed petition or its tracking receipt is not that publication.

The commercial-release gate is not a blanket ban on premarket shipments. Devices or IVDs imported for clinical investigations, or samples for non-commercial tests, teaching or training, may require a different ANVISA import-consent route with purpose-of-use restrictions. Do not sell or divert such shipments to routine clinical use without the legally required permissions. Check the declared import purpose before dispatch.

Registration execution belongs to a separate workflow

This page owns the combined regulatory stack for a specified medical device. It does not repeat petition codes, fees, deadlines or dossier upload procedures. For execution, see the Brazil medical-device registration services guide. For body-worn sensors and other worn devices, the separate Brazil wearable-medical-device route map addresses wearable-specific intended-use, battery, skin-contact and connectivity boundaries.

Official regulatory sources

Key official sources (check for later amendments)

Product-specific questions

Is every medical device in Brazil subject to an INMETRO certificate?: No. Mandatory SBAC certification depends on the relevant equipment or commodity regulation and the current ANVISA normative list. Classify the exact product and check its scope; ANVISA notification/registration and product conformity certification are distinct steps.
Can a Class II medical device be sold immediately after the manufacturer files a notification?: Do not equate filing with unconditional permission. Confirm that ANVISA has processed the applicable notification and issued the identifying number, that the filed product matches the marketed configuration, and that any other mandatory approvals and business permissions are in place. Check the grant’s publication in the Diário Oficial da União (DOU) before sale.
Is a diagnostic test kit regulated in the same way as a treatment instrument?: Not automatically. A device analysing human specimens follows the IVD framework in RDC 830/2023, including its own class rules and performance evidence. A treatment device usually follows RDC 751/2022. Describe exactly what the product does before selecting the rule.
Do CE marking or FDA approval replace ANVISA registration?: No automatic substitution follows from either. Foreign approvals may support the technical package or a specifically available ANVISA reliance mechanism, but eligibility, sameness and Brazilian filing obligations must be checked for the exact device.
What changes if our device includes Bluetooth or an AI diagnostic function?: Assess the radio function for ANATEL separately and the software claims against RDC 657/2022 and the applicable ANVISA device/IVD rules. The existence of Bluetooth or AI alone does not determine the risk class or guarantee which extra approval is required.
Does importing an accessory or replacement part always require AFE?: No single rule fits all components. ANVISA’s December 2024 clarification distinguishes spare parts and accessories included in a finished-device regularisation from separately regularised accessories, whose importers need AFE. Import consent may still be needed. Check classification, filed scope and importer activity.